|
|
Blood, 1 July 2005, Vol. 106, No. 1, pp. 328-337.
Prepublished online as a Blood First Edition Paper on March 22, 2005; DOI 10.1182/blood-2004-09-3686.
Previous Article | Next Article 
Submitted September 24, 2004
Accepted March 9, 2005
Constitutively activated FGFR3 mutants signal through PLC -dependent and -independent pathways for hematopoietic transformation
Jing Chen*, Ifor R Williams, Benjamin H Lee, Nicole Duclos, Brian J Huntly, Daniel J Donoghue, and D G Gilliland
Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA
Department of Pathology, Emory University, Atlanta, GA, USA
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
Department of Chemistry and Biochemistry, Univeristy of California-San Diego, La Jolla, CA, USA
* Corresponding author; email: jchen{at}rics.bwh.harvard.edu.
Ectopic expression of FGFR3 associated with t(4;14) has been implicated in the pathogenesis of human multiple myeloma. Some t(4;14) patients have activating mutations of FGFR3 of which a minority are K650E (TDII). To investigate the role of autophosphorylated tyrosine residues in FGFR3 signal transduction and transformation, we characterized a series of FGFR3 TDII mutants with single or multiple Y F substitutions. Phenylalanine substitution of Y760, essential for PLC binding and activation, significantly attenuated FGFR3 TDII-mediated PLC activation, as well as transformation in Ba/F3 cells and a murine bone marrow transplant leukemia model. In contrast, single substitution of Y577, Y724 or Y770 had minimal to moderate effects on TDII-dependent transformation. Substitution of all the four non-activation loop tyrosine residues significantly attenuated, but did not abolish TDII transforming activity. Similar observations were obtained in the context of a constitutively activated fusion TEL-FGFR3 associated with t(4;12)(p16;p13) peripheral T-cell lymphomas. Moreover, two independent EµSR-FGFR3 TDII transgenic mouse lines developed a pro-B cell lymphoma, and PLC was highly activated in primary lymphoma cells as assessed by tyrosine phosphorylation. These data indicate that engagement of multiple signaling pathways, including PLC -dependent and PLC -independent pathways, is required for full hematopoietic transformation by constitutively activated FGFR3 mutants.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. R. St-Germain, P. Taylor, J. Tong, L. L. Jin, A. Nikolic, I. I. Stewart, R. M. Ewing, M. Dharsee, Z. Li, S. Trudel, et al.
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition
PNAS,
November 24, 2009;
106(47):
20127 - 20132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Salazar, T. Kashiwada, P. Krejci, P. Muchowski, D. Donoghue, W. R. Wilcox, and L. M. Thompson
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells
Hum. Mol. Genet.,
June 1, 2009;
18(11):
1951 - 1961.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Y. Cha, S. Maddileti, N. Mitin, T. K. Harden, and C. J. Der
Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform
J. Biol. Chem.,
March 6, 2009;
284(10):
6227 - 6240.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Loriaux, R. L. Levine, J. W. Tyner, S. Frohling, C. Scholl, E. P. Stoffregen, G. Wernig, H. Erickson, C. A. Eide, R. Berger, et al.
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Blood,
May 1, 2008;
111(9):
4788 - 4796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Dong, S. Kang, T.-L. Gu, S. Kardar, H. Fu, S. Lonial, H. J. Khoury, F. Khuri, and J. Chen
14-3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells
Blood,
July 1, 2007;
110(1):
360 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Rocnik, R. Okabe, J.-C. Yu, B. H. Lee, N. Giese, D. P. Schenkein, and D. G. Gilliland
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Blood,
August 15, 2006;
108(4):
1339 - 1345.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|